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To date, there has been only one study comparing costs of outpatient versus inpatient 
TSA. This study sought to understand the differential costs, complications, and 
readmission rates between TSAs performed in an outpatient versus inpatient setting in 
lieu of the Affordable Care Act and ICD-10. Archival data were obtained from Medicare 
5% limited data set and MarketScan® privately insured billing data from 2016 for patients 
aged 55-74, propensity score matching 1:1 to ensure similar propensity for surgery in the 
outpatient setting. In total, 1,578 patients underwent TSA in our dataset: 374 outpatient 
and 1,204 inpatient. Following propensity score matching, 738 well-matched TSA 
patients were included in this study—369 each in inpatient and outpatient. In adjusted 
analysis, total costs for inpatient TSA were 87% higher than outpatient $36,033 vs. 
$19,253 (p=0.0001). For overall complication rates, inpatient TSAs had an approximately 
54% overall lower odds of a medical or surgical complication than those performed in an 
outpatient setting (Odds ratio [OR] 0.436, 95% CI: 0.236-0.806, p=0.008). In conclusion, 
our results show that outpatient TSA provides a significant cost reduction. However, 
there was an increase in odds of complication, which is contrary to previous work. 
Therefore, future work should focus on evaluating outpatient TSA, its value, and its 
safety within ICD-10 and the ACA. Additionally, healthcare leaders should focus on 
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  Osteoarthritis (OA) is an age-associated disease that affects millions of people in 
the United States (WHO, 2010).  According to the Centers for Disease Control and 
Prevention (CDC, 2018). OA diagnosed by physicians will reach 25.9% of adults over 
age 18 by 2040, nearly 78.4 million Americans.  
 The leading indication for OA is total joint arthroplasty (TJA) (Sloan & 
Hanrahan, 2014; Kurtz, et. al., 2007). As the prevalence of OA continues to increase, so 
will the need for TJA surgery. Shoulder osteoarthritis, in particular, and the resulting 
treatment of total shoulder arthroplasty (TSA), has grown at a rate of 9.4% annually in 
the United States and is projected to exceed that of total knee arthroplasty (TKA) and 
total hip arthroplasty (THA) (Day et al., 2010). While TSA is largely performed on the 
elderly, in the US it is increasing at a rate of 12.1% annually for those over the age of 55 
years old. Furthermore, the procedure is also being used for younger people as well. 
Between 2002-2011, the rate of increase in TSA for patients under 55 years old was 8.2% 
in the US (Kim, Kim, Wise, Zhang, & Szabo, 2011; Padegimas, Maltenfort, Lazarus, 
Ramsey, Williams, & Namdari, 2015). 
 Historically, TJA and TSA have proven to be safe procedures. Surgeons have 
translated their good outcomes from inpatient TJA into the outpatient setting with good 
results. These outcomes have motivated orthopedic surgeons to increase the use of TSA 




increased, researchers have evaluated its safety in the outpatient setting and found it to be 
safe (Famer et al., 2007; Fehrigner et al., 2007).   
 In the outpatient setting, it is vital to avoid costly complications and readmissions. 
Postoperative complications and unplanned hospital admissions following outpatient TJA 
and TSA can increase costs following the procedure. In turn, this will decrease the value 
associated with outpatient TSA. Healthcare providers need to be aware of patients that 
are considered to be high-risk for complications following TSA and encourage those 
patients to have surgery performed in an inpatient setting. Decreasing costly 
complications will decrease the costs associated with inpatient TSA such as overnight 
charges, hospital charges, nursing, labs, and medications (Crawford, Li, Sprague, & 
Bhandari, 2015) In fact, Previous studies have shown the three major drivers for cost are 
operating room costs, medical device costs, and length of stay in the hospital (Bosco, et 
al., 2014; Healy et al., 1998; Healy et al., 1998; Raphael et al., 2014; Steinhaus et al., 
2018). While intraoperative costs, such as operating room time and surgical implants may 
be common to both inpatient and outpatient TSA surgery, elimination of the inpatient 
stay altogether can eliminate the third major cost driver— assuming the correct patients 
are chosen for outpatient TSA.  
 Using protocols and care pathways to educate patients, identify high-risk patients 
for complications, and redirecting those patients toward inpatient TSA is paramount to 
successful implementation of outpatient TSA (Kim and Iorio, 2017; Brolin and 
Throckmorton, 2018; Lombardi et al., 2016). These protocols and pathways will 




risk patients to have their surgeries performed in the inpatient setting; low risk patients 
would be encouraged to have their surgery performed in an outpatient setting, decreasing 
costs.  Moreover, it will create a perioperative environment promoting success by 
following the aforementioned principles for outpatient TSA patients, thus decreasing 
complications and unplanned hospital admissions. These complications and unplanned 
hospital admissions following inpatient and outpatient TSA can be costly. 
 Healthcare spending in the United States is increasing dramatically and healthcare 
leaders are looking for ways to decrease costs and encourage value. Current spending in 
the US is nearly $3.5 trillion annually, or nearly 18% of the Gross Domestic Product 
(Berland, Rocco & Walden, 2015; Bryan, 2016). Therefore, value is crucial to the future 
to of our healthcare system. Value is defined as “health outcome per dollar of cost 
expended” (Porter & Olmsted-Teidsberg, 2006, p.4). Therefore, healthcare experts are 
focused on finding strategies to improve outcomes and decrease costs. According to 
Porter & Olmstead-Teidsberg, they believe “the structure of healthcare delivery” is 
essential to the success of our healthcare system (Porter & Olmstead-Teidsberg, 2006, 
p.3).  
 As the volume of TJA and TSA increases in the United States healthcare leaders 
are focused on value and the “structure of healthcare delivery” (Porter & Olmstead-
Teidsberg, 2006, p.3). One option being discussed and studied by the Centers for 
Medicare and Medicaid Services (CMS), to decrease the costs of TJA , is through the 
Bundled Care Payment Initiative (BPCI). The BPCI process was designed to create value 




process will assist CMS in working to foster an environment where physicians, hospitals, 
and post-acute care providers strive for interoperability and streamlining quality care to 
these patients. As TJA is considered a costly procedure, this program is designed to 
increase productivity, drive down costs, and increase value associated with the 
procedures (CMS, 2018). 
 As researchers continue to investigate BPCI as a cost-saving strategy for TJA, 
outpatient TJA and TSA have become more popular. Approximately 60% of all surgeries 
done in the United States in 2011 were outpatient (ASCA, 2011). Further, outpatient TJA 
has been shown to be cost-effective in the past (Aynardi et al., 2014; Crawford, Li, 
Sprague & Bhandari, 2015; Lovald et al., 2014). This research has provided the 
motivation to demonstrate the cost effectiveness of inpatient TSA (Crawford et al., 2015; 
Mather et al., 2015). As inpatient TSA costs could vary from $1500-$12,500 per day, 
these costs could be completely avoided by utilizing outpatient TSA (Steinhaus et al., 
2018).  
 TJA is the largest procedural consumer of Medicare’s budget at 6.3% annually 
(Dobson et al., 2012). Outpatient TSA is one way to decrease these costs and increase 
value for consumers to ensure the solvency of the US healthcare system. To date, there 
has been little work focused on comparing outpatient TSA versus inpatient TSA and the 
potential cost savings. This study will ameliorate this problem by selecting only patients 
in both inpatient and outpatient settings who could genuinely have their surgery done in 




 This study has been designed to determine the marginal cost differences of total 
shoulder arthroplasty performed in an outpatient setting compared with that same 
procedure performed in an inpatient setting in a well matched group of low to medium 
risk patients, with the following aims: 
Aim 1 
 To determine if outpatient total shoulder arthroplasty offers a cost advantage over 
the inpatient setting among patients with similar preoperative risk and treatment. 
Aim 2 
To determine the demographics of inpatient total shoulder arthroplasty versus 
total shoulder arthroplasty in an ambulatory surgery center and outpatient surgery. 
Rationale of Importance 
 As value is becoming increasingly important, healthcare leaders must continue to 
seek out and find ways to balance cost savings with uncompromising patient safety. 
Outpatient TSA should not be an option for every patient; likewise, inpatient TSA should 
not be a consideration for every patient. Healthcare providers and patients need to be 
responsible enough to avoid costly errors by treating those patients with significant 
medical risks as inpatient. However, providers and patients should also encourage value 
by facilitating outpatient TSA for those patients who qualify. As our population ages, 
increasing numbers of people will develop osteoarthritis, resulting in increased need for 
TSA, which will drive up healthcare costs. Therefore, healthcare leaders should strive to 





REVIEW OF THE LITERATURE 
Population & Osteoarthritis 
 The United States population is aging and by 2050 there will be a substantial growth of 
Americans over 65 years old. The baby boomers have contributed to the increase in elderly 
Americans as those over the age of the 65 are estimated to be 83.7 million (Ortman,Velkoff, & 
Hogan, 2014). As this aging of America’s population occurs, there will also be an increase in 
age-associated pathologies. Healthcare experts will need to be aware of these changes and 
equipped to handle them.  
 One such age-associated disease is osteoarthritis (OA). Osteoarthritis is the sixth leading 
cause of years lived with disability (YLD) in the world (WHO, 2010). According to the Centers 
for Disease Control (CDC, 2018), there are approximately 54.4 million adults in the United 
States who have been diagnosed with OA, which is approximately 22.7% of the US population. 
Furthermore, nearly 43.5% of those with the diagnosis of OA admit to limitations of their daily 
activities associated with the disease. This could contribute to decreased activity levels and 
encourage other diseases such as obesity, diabetes, and cardiovascular disease.  The CDC 
estimates that doctor-diagnosed OA to reach 25.9% of adults over the age of 18 by 2040, 
equaling approximately 78.4 million Americans (Ibid).  
Total Joint Arthroplasty & Volume  
 Currently, OA is the leading indication for total joint arthroplasty (TJA) (Kim et al., 
2011). As a result, the numbers of the TJAs performed have grown tremendously. Between 2005 
and 2030, total hip arthroplasties are expected to increase 174% and total knee arthroplasties 




arthroplasties and 572,000 total hip arthroplasties in the United States per year by 2030 (Sloan & 
Hanrahan, 2014; Kurtz, et. al., 2007). According to the Organisation for Economic Co-operation 
and Development knee replacements grew by 50% (143 to 213 TKA per 100,000 people in the 
US ) in 2017 and hip replacements grew by 35% (185 to 226 people per 100,000 people in the 
US) followed closely at 35% (OECD, 2018; Lam, et al., 2018).  
Total Shoulder Arthroplasty & Volume 
 The primary reason for total shoulder arthroplasty is osteoarthritis. Therefore, total 
shoulder arthroplasty (TSA) is increasing at a fast rate with a growth of 9.4% annually in the US 
and projections are exceeding those of lower extremity arthroplasty (Day et al., 2010; Kim et al., 
2011).  Day et al. (2010) found procedural volumes increasing 6 to13% in  annually from 1993-
1997; and from 2007-2015 increases in projected annual rates were projected to increase 192 to 
322%. These increases will necessarily increase the revision burden of TSA, as well. Kim et al., 
(2011) showed two-thirds of the TSAs performed in the US were performed on the elderly (65 
years and older).  
  Researchers have shown an increase in TSA 3.5 times higher than before 2000 (Kim et 
al., 2011).  There are at least five reasons for this increase in TSA. First, Kim et al. (2011) 
suggest it could be a result of the introduction of the reverse total shoulder arthroplasty (RTSA). 
The RTSA could have provided a correction in the numbers secondary to treating rotator cuff 
arthropathies, not normally treated by anatomic TSA. Prior to the RTSA, patients with rotator 
cuff arthropathies would undergo a hemiarthroplasty or forgo surgery. Second, there is likely a 
growing acceptance, or mainstreaming, of TSA secondary to its increase use and success. This 
acceptance will lead to more training programs, resulting in more specialty trained shoulder 




improvement in perioperative pain control has also increased the ability of surgeons to do more 
volume. Better methods of pain control will encourage successful TSA procedures and motivate 
other patients to have the procedure (Brolin & Throckmorton, 2018). Fifth, and finally, the 
percentage of the elderly in the US is rising—which is the group that undergoes the most TSAs 
(Kim, et al., 2011). 
 The demand for TSA is growing among other demographics as well. There has also been 
an increase in the demand for TSA in younger patients. Padegimas et al. (2015) evaluated the 
demand for those patients younger than 55 years old between 2002-2011. The rate of TSA 
increased 8.2% annually among those under the age of 55 years old and 12.1% for patients over 
55 years old. Further, overall from 2002 to 2011, their research suggested an increase of 755.4% 
in TSA within this demographic. However, they noted the need for TSA in younger patients less 
than 55 years old will triple between 2011-2030 (Padegimas et al., 2015). 
Safety of Total Joint Arthroplasty 
 Historically, authors have used evidence from total knee arthroplasty (TKA) and total hip 
arthroplasty (THA) to explain the importance of examining TSA. Researchers have used studies 
to prove the safety of TJA. Successful approaches to total knee arthroplasty (TKA) and total hip 
arthroplasty (THA) have provided the impetus for ambulatory TSA.  Past studies have shown 
TJA to be safe. 
  Berger, Sanders, Sporer, & Della Valle (2009) and Berger, Kusuma, Sanders, Thill, & 
Sporer, S. M. (2009). demonstrated in two separate studies the safety and efficacy of outpatient 
total hip and total knee arthroplasties. Additionally, Courtney et al. (2016) conducted a database 
analysis of patients receiving THA and TKA between 2011-2014. The authors propensity score 




versus inpatient 16%. Lovald et al. (2014) evaluated short stay TKA and found a lower 
complication and readmission rate for those undergoing an outpatient or 1-2 days stay following 
TKA. The patients in this group also showed lower Charlson morbidity scores and tended to be 
healthier than those patients staying the standard 3-4 nights inpatient. However, not all studies 
have shown a reduction in readmissions following outpatient TJA. Springer et al (2016) 
evaluated TKA and THA from 2010-2011 and found inpatient TJA to have lower readmission 
rates than outpatient. While the numbers were not statistically significant, the outpatient TJA 
readmission rate was 11.7% compared to the inpatient at 6.6% (Springer et al., 2016)  
Additionally, Springer et al. (2016) emphasizes the importance of identifying those morbidities 
increasing the rate of adverse events, complications, and readmissions following TSA.  
Total Shoulder Arthroplasty & Complication Risk Factors 
 Previous studies in TJA have shown certain demographics and morbidities associated 
with increased complications. Patients with a history of smoking, cardiac disease, diabetes, 
malnutrition, and patients greater than 70 years old were at higher risk and this was statistically 
significant (Courtney et al., 2017).  
 Recognizing risk factors for complications and hospital readmissions to the hospital will 
prevent associated unnecessary costs. Dunn et al. (2015) conducted a retrospective analysis of 
2004 patients between 2005 and 2011, to evaluate predictors of length of stay (LOS) after TSA. 
These patients had an average age of 68.8 years, with an average LOS for these patients was 2.2 
days. They identified several risk factors for increased postoperative length of stay 
postoperatively: renal insufficiency, it looks like in well matched groups between inpatient and 
outpatient the length of stay was similar cardiac disease, advanced age (>65 years old), American 




(Dunn et al., 2015). Controlling for these risk factors during preoperative assessment by treating 
other medical comorbidities could decrease length of stay. Further, educating patients prior to 
surgery is paramount as proper education will inform the patients regarding potential risks and 
could prevent return to the ED.  
 Basques et al. (2017) compared outcomes of patients undergoing TSA inpatient versus 
outpatient. They retrospectively analyzed 123,347 Medicare patients between 2005-2012, 
matching age, gender, and medical morbidities. Overall, they found outpatient TSA was safer 
among younger and healthier patients: The outpatient cohort demonstrated a lower 30 and 90-
day readmission rate and complication rates compared to the inpatient cohort. Among those in 
the inpatient cohort, the authors identified a higher percentage of women, and higher rates of 
smoking, diabetes, coronary artery disease, congestive heart failure, and chronic kidney disease. 
Moreover, complications were also higher in this group including thromboembolic events and 
surgical site infections. In all, this article indicates patients who had a TSA in an outpatient 
setting tended to be healthier and younger, whereas those patients who had a TSA in an inpatient 
setting tended to have increased medical morbidity and higher rates of complications.  
 The findings from Cancienne et al. (2017) supported the other studies by showing the 
importance of selecting appropriate patients for ambulatory TSA. The authors looked at 706 
patients who underwent ambulatory TSA nationwide. The patients were propensity score 
matched to 4,459 inpatient TSAs. The authors analyzed numerous demographic variables and 
risk factors for readmission including age, sex, diabetes, tobacco use, chronic kidney disease, 
coronary artery disease, Charlson Comorbidity Index (CCI), chronic anemia, and obesity. The 




was no difference in the rate of readmission in the 90 days following surgery. As a result, the 
authors noted the importance of choosing appropriate patients for ambulatory surgery.  
 Identifying risk factors for complications and readmission is important in order to reduce 
costs associated with TSA. Developing methods to identify risk factors and prevent readmissions 
is equally important. One method is utilizing protocols and care pathways.  
Outpatient Total Shoulder Arthroplasty & Safety  
 As outpatient TSA becomes more common, we must be cognizant of ways to increase 
safety and improve outcomes. Researchers have evaluated TSA, and comparing it to TKA and 
THA and have found it to also be safe in an inpatient setting. Famer et al., (2007) analyzed 
34,471 inpatient TKAs, 994 inpatient TSAs, and 15,414 inpatient THAs and the complication 
rate for TSAs was just 7.6%, whereas the rates among THA was15.5% and TKA 14.7%. 
Fehringer et al. (2007) completed a study of the Veteran’s Administration showing a 30-day 
complication rate of only 2.8% for inpatient TSA patients compared to 6.8% inpatient TKA and 
7.6%, inpatient THA. Brolin et al., (2017) demonstrated in a small cohort of 30 patients the 
average length of stay (LOS) for TSA patients was approximately 1.1 days. These studies 
support the safety and success of inpatient TSA vs. TJA. 
 Waterman et al. (2015) evaluated TSA and its morbidity and mortality for 30 days 
following the procedure. The mortality was 0.25% while the complication rate was 3.64%. 
Peripheral vascular disease significantly increased the risk of complications as well as longer 
operating room times. Thus, decreasing length of stay at hospitals and choosing to utilize 
ambulatory TSA has been shown to be safe and effective.  
  Farng et al. (2011) showed short term complication rates are very similar to those of long 




was higher in those patients receiving a hemiarthroplasty secondary to a fracture compared to 
primary anatomic TSA for osteoarthritis. The difference in these cohorts could be explained by 
the medical comorbidities. Fractures are less likely to be elective procedures, while primary 
TSAs are elective surgeries requiring more medical screening, thus decreasing the likelihood of 
complications following surgery. 
 Decreasing complications and readmissions is important to reduce costs. Duchman et al. 
(2017) showed a lower rate of postoperative complications between outpatient TSA and inpatient 
TSA cohorts. The researchers found a complication rate of 1.8% versus 5.0% for the outpatient 
and inpatient cohorts, respectively. However, the short stay patients (discharged on postoperative 
day 0 to 1) were younger with an average age of 67.6 years . Further, the short stay patients were 
less likely to having medical comorbidities associated with complications and readmissions such 
as coronary artery disease, diabetes, obesity, and chronic obstructive pulmonary disease (COPD). 
 Likewise, Nwankwo et al. (2018) evaluated the 90-day risk of complications for patients 
receiving outpatient TSA versus inpatient TSA. After propensity score matching on baseline 
characteristics, their results were statistically significant, as they found no differences in rates of 
readmission, emergency department visits, morbidity within 90 days of surgery or mortality 
(Nwankwo et al., 2018).  
 After propensity score matching patient demographics, Leroux et al. (2016) compared  
outpatient to inpatient TSAs, finding the 30-day readmission rate for outpatient TSA to be 1.74% 
compared to the inpatient 2.93% among patients in an inpatient setting. Moreover, the 30-day 
adverse event rate was even more impressive the outpatient cohort adverse rate was 2.31% 




adverse event rates for outpatient versus inpatient TSA, yet the numbers were not statistically 
significant. 
 Brolin et al. (2017) propensity score matched age and comorbidities in a small cohort of 
30 patients comparing inpatient and outpatient TSA patients. The authors evaluated a 90-day 
time frame monitoring the patients’ care--including readmissions, reoperations, and 
complications. Twenty-seven of the 30 patients were sent home postoperatively on day 1. The 
remaining three patients were sent home the following day. The average length of stay for the 
inpatient cohort was (1.1) days. No significant differences between inpatient and outpatient 
cohorts were found for age, body mass index, and American Society of Anesthesiologists (ASA) 
scores. The complication rates were not statistically different, with 10% versus 13% for 
outpatient TSA versus inpatient TSA, respectively. 
 Avoiding costly complications and readmissions will encourage the implementation of 
outpatient TSA. Identifying risk factors associated with complications and readmissions to the 
hospital following TSA is paramount.  
Outpatient Total Joint Arthroplasty – Protocols & Pathways 
 Pathways and protocols are helpful to identify high-risk patients to both prevent 
postoperative complications and to choose the ideal surgical setting — whether inpatient or 
outpatient. Moreover, these pathways could provide a means to avoid readmissions and 
complications, thus decreasing costs, securing good outcomes, and ultimately increasing value. 
 The most common demographic for outpatient surgery centers is adult females 45-60 
years of age (Cullen, Hall, & Golosinskiy, 2009). While risk factors for complications are likely 
lower in this demographic, patient selection is vitally important for successful implementation of 




complications prior to elective anatomic TSA are vital to prevent postoperative complications. 
Outpatient TSA requires healthcare professionals to properly evaluate those patients and direct 
at-risk patients to inpatient settings. In turn, this redirection of at-risk patients will decrease the 
risk of potential complications and decrease costs. There is a correlation between preoperative 
medical morbidities and post-operative complications (Chalmers et al., 2014). 
 Lovett-Carter et al. (2018) and Berger et al. (2009) noted the safety of outpatient TJA 
(TKA and THA) and recommended the use of pathways and protocols to identify high-risk 
patients and prevent postoperative complications. Using these standardized protocols and 
pathways requires a multidisciplinary approach for those patients to be successful. Otherwise, 
these patients could be at a higher risk for readmission or visits to the emergency department.  
 Chalmers et al. conducted a retrospective review of patients receiving a primary anatomic 
TSA and the complication rate for these patients was 9.4% at 90 days postoperatively. In this 
study, the Charlson Comorbidity Index (CCI) demonstrated are complication rates and TSA 
(p<.05). Thus, surgeons should use the comorbidities represented in CCI to help them predict 
potential complications and those patient with higher CCI should be directed toward inpatient 
TSA. 
 Three separate articles have provided insight into protocols and pathways. First, while 
studying Bundled Payment Care Initiative (BPCI), Kim and Iorio (2017) provided five clinical 
pillars for success to reduce complications and cost drivers. 
1. Optimize patient selection and comorbidities 
 The researchers noted that medical comorbidities can increase the risk for complications 




of these medical problems included hypertension, hyperlipidemia, tobacco use, and 
diabetes.         
2. Optimize Care Coordination/Patient Education/Expectations 
 Parties can mitigate potential risks by educating patients regarding the potential risks 
associated with the procedure, in relation to their own medical comorbidities, and by 
streamlining the various pathways based on each patient, this will mitigate the potential 
risks for complications. Providing standardized care plans and promoting provider to patient 
and intra-provider communication has been shown to foster value-driven care. Kim and 
Iorio (2017) noted their institutional goals have been to encourage “collaborative decision-
making” amongst the providers and to streamline the process by maintaining more than 
80% of the standardized care to remain in their care pathways (p. 1714).  
3. Multimodal analgesia for TJA 
 Analgesic techniques such as administration of NSAIDs, opioids, nerve blocks, and 
liposomal bupivacaine accelerate the postoperative process by encouraging early range of 
motion, mobilization, and physical therapy.  Of course, each of these techniques promotes 
an earlier recovery by the patient, decreases the likelihood of complications related to the 
TJA, and decreases length of stay. 
4. Risk-stratified VTED prophylaxis  
 Any lower extremity surgery has increased the risk of venous thrombosis embolism (VTE). 
Considered a complication of TJA, VTE requires rehospitalization, thus increasing the 
postoperative costs of TJA. Currently, there are different forms of VTE prophylaxis 
including aspirin, Coumadin, low-molecular weight heparin, sequential pneumatic 




mobilization can discourage the development of VTE. As noted earlier, it is important to 
consider each patient individually, and encourage those patients to follow the care pathway 
or algorithm (Kim & Iorio, 2017). 
5. Minimize Post-Acute Facility and Resource Utilization  
Admitting a patient to a skilled-nursing facility or other post-acute rehabilitation facilities 
can be quite costly to our healthcare system. Furthermore, extended stays in these types of 
facilities could increase one’s risks of complications such as infection and VTE, will further 
increase costs. Utilizing a multidisciplinary collaborative approach to TJA patients 
preoperatively, intraoperatively, and postoperatively is a necessity to avoid expensive 
readmissions. Each member of the team needs to be functioning under the same goals, thus 
encouraging quality and value-based care (Kim & Iorio, 2017). 
 The second important article that helps us to understand clinical protocols and pathways 
is Brolin and Throckmorton (2018). This article helps affirm these pillars by noting the 
importance of the following:  
1. patient selection 
2. pain management 
3. limiting intraoperative blood loss 
4.  patient education.  
 Lastly, Lombardi et al. (2016) provided their care pathway as the “Ten Steps for 
Successful Execution of Outpatient Arthroplasty” as follows: 
1. Orthopaedic assessment 
1. Preoperative medical clearance 




3. Preoperative physical therapy 
4. Preoperative analgesic agents 
5. Perioperative anesthetic agents 
6. Efficient performance of the surgical procedure 
7. Wound healing adjuncts 
8. Establishment of clinical pathways 
9. Explicit post discharge instructions 
 Each of these articles provided by Kim and Iorio (2017), Brolin and Throckmorton 
(2018), Lombardi et al. (2016) emphasizes the importance of patient selection. This patient 
selection includes avoiding those patients who would increase the risk of complications and 
readmissions. As unplanned admissions are being more heavily scrutinized by Centers for 
Medicare and Medicaid Services (CMS) and insurance companies and Bundled Payments for 
Care Improvement Initiative (BCPI) gains momentum, the aforementioned protocols and 
programs will become increasingly important. Following the aforementioned protocols will 
enable healthcare providers to provide the best evidence-based care possible while limiting 
wasteful spending. Outpatient TSA could potentially reduce length of stay and the additional 
secondary costs associated with a longer length of stay. Utilizing the aforementioned pathways 
and protocols could assist in this reduction and encourage outpatient TSA as a value-driven 
option compared to inpatient TSA. 
Total Joint Arthroplasty & Costs 
  In the United States, healthcare spending is nearly $3.5 trillion annually, which is 
nearly18% of the Gross Domestic Product (GDP); on average this is approximately $9990 per 




focused upon the costs of TJA its cost; at 6.3%, it is the largest procedural consumer of 
Medicare’s budget (Dobson et. al., 2012). As a result, healthcare leaders have been seeking 
strategies to decrease expenses associated with total joint arthroplasty.  
 Historically, there has been plenty of research evaluating costs savings associated with 
performing outpatient TKAs and THAs in outpatient versus inpatient settings. Typically, these 
studies find cost savings in performing these procedures in outpatient settings. For instance, 
Aynardi et al. (2014) showed a cost reduction in outpatient THA compared to inpatient,  $24,529 
versus $31,327, respectively (p=0.0001). Lovald et al. (2014) examined the costs of ambulatory 
TKA demonstrating an average costs savings of $8,527 per patient. Other researchers in a 
systematic review showed multiple procedures with a costs savings ranging from 17.6% to 
57.6% decrease for outpatient surgical procedures (Crawford, Li, Sprague & Bhandari, 2015).  
 Improving outcomes, decreasing costs, and consequently increasing value is vital to the 
solvency of our healthcare system. We must train our healthcare providers to be cost-conscious 
and value-driven during their education. This training will instill a culture of value and 
sustainability necessary for innovative procedures such as outpatient total joint arthroplasty. 
Bundled Care Payment Initiative (BCPI) 
 One option currently being discussed and studied to decrease costs for TJA is the 
Bundled Care Payment Initiative (BPCI). One subprogram of the BPCI is the conference of care 
for joint replacement model (CJR). In 2016, CMS began a pilot program that would last for 5 
years and using 67 different areas around the country, known as Metropolitan Statistical Areas 
(MSAs; urban center with a population of 50,000 or greater)(CMS, 2018). These areas are urban 
centers with a population of 50,000 or greater. Prior to implementation, CMS collected data 




the program. This model is known as the Comprehensive Care for Joint Replacement Model 
(CJR) and will serve as a CMS pilot for bundling total hip and knee arthroplasties, while 
attempting to create more efficiency with total knee and total hip arthroplasties. These 
procedures, defined by CMS as lower extremity joint replacements, are known as the costliest in-
patient procedures for CMS. This pilot is responsible for evaluating each episode of care and 
testing the efficiency and quality of the bundled payment. During this process, CMS will work to 
foster an environment where physicians, hospitals, and post-acute care providers strive for 
interoperability and streamlining quality care to these patients. This model is expected to 
increase productivity, drive down costs, and increase value associated with the procedures 
(CMS, 2018). 
 The CJR model promotes a value-driven paradigm by incentivizing each stakeholder 
involved in the TJA episode of care through TJA increasing financial accountability, 
encouraging quality care, and fostering coordination amongst stakeholders (CMS, 2018). 
Patients will promote a value-driven paradigm. Beneficiaries begin their episode of care by being 
admitted to the hospital; this begins a 90-day period on the day of admission. These patients 
must have been seen for major joint replacement of the lower extremity, defined as having their 
stay coded under one of the following diagnosis-related groups (MS-DRG) (CMS, 2018): 
• MS-DRG 469 – major joint replacement or reattachment of lower extremity with major 
complications or comorbidities, or  
• MS-DRG 470 – major joint replacement or reattachment of lower extremity without 
major complications or comorbidities  
 In the CJR model, each episode includes all services or devices paid for under Medicare Part A 




related to the stated DRGs will be evaluated annually. Target pricing will be compared to actual 
pricing and CMS will evaluate performances setting new reimbursement goals for the hospitals. 
CMS will employ a performance-based analysis of sort; if the hospital is under its expense goal, 
then they could be reimbursed the difference. However, if they exceed the stated expense goals, 
they could be forced to repay some of their expenses. During this 90-day global period, any 
complications or readmissions related to surgery will drive the costs upward and decrease any 
profits realized under the bundled payment, as the hospital and physician could be responsible 
for the costs (CMS, 2018). This additional cost could be especially pertinent to outpatient TJA. 
Patients released from ambulatory surgery centers or hospitals postoperatively could visit the 
emergency department, or even be admitted to the hospital, due to surgical complication, thus 
increasing costs. Moreover, patients could possibly be admitted to the hospital, thus increasing 
costs. This cost increase could be a potential large loss of revenue for the stakeholders--the 
outpatient surgery center, hospital, and provider--if outpatient TJA is not implemented 
appropriately by correctly choosing the most appropriate patients. 
 Previous studies have shown there are three major cost drivers for surgery: operating 
room costs, medical device costs, and length of stay in the hospital (Bosco, et al., 2014; Healy 
eta al., 1998a; Healy et al., 1998b; Raphael et al., 2014; Steinhaus et al., 2018). As a result, 
programs like BPCI encourage surgeons to focus on patient selection, medical comorbidities, and 
directing appropriate patients who qualify toward an outpatient setting for surgical care, there 
could be potential cost savings. By minimizing length of stay and directing qualified patients 
toward outpatient settings, there could be potential cost savings. However, no study to date has 
investigated if cost savings are possible among patients undergoing TSA in an outpatient setting 




Outpatient Total Shoulder Arthroplasty– Costs & Value 
 As the healthcare environment continues to change, resources are becoming limited and 
increasing value is permanently at the forefront of this change. As greater emphasis is placed on 
achieving high quality outcomes while also containing costs, value becomes increasingly 
important. According to Porter and Olmstead-Teidsberg (2006), strategically healthcare can be 
divided into three categories: “cost of and access to health insurance, standards for coverage or 
the types of care that should be covered by insurance versus being the responsibility of the 
individual, and the structure of healthcare delivery itself” (p.3). They believe the structure of 
healthcare delivery is essential to the success of our healthcare system (Porter & Olmstead-
Teidsberg, 2006). Competition and quality are very important in the free market and there is 
great emphasis placed on value. In healthcare, this translates to “health outcome per dollar of 
cost expended” (Porter & Olmsted-Teidsberg, 2006, p.4).  
 Thus, decreasing healthcare expenditures is vital to the solvency of our healthcare 
system. Furthermore, all things being equal for similar health outcomes and similar rates of 
complications, that given two options for treatment the low cost option is the one with greater 
value.  
 Outpatient TSA and TJA are part of a general trend in healthcare, increasing focus on the 
patient, decreasing unnecessary medical procedures, thus increasing value (Lombardi et al., 
2016). According to the Ambulatory Surgery Association (ASCA) approximately 60% of all 
surgeries performed in 2011 were done in an outpatient setting (ASCA, 2011).  The increase in 
outpatient TJA and TSA could represent a response to the CMS and BPCI. As healthcare 
providers strive for cost containment and value, they will be motivated to potentially increase 




might incentivize providers to utilize surgery centers for TSA, yielding cost savings. By 
decreasing the length of stay, other downstream cost drivers will decrease such as overnight 
hospital charges, nursing, therapy, labs, medications, and other studies, and consequently, overall 
costs will go down (Crawford et al., 2015). This is where real cost savings are realized through 
TSAs performed in an outpatient setting. 
  While there is little research evaluating the differential costs of outpatient TSA, there is 
ample research evaluating the costs associated with the conditions necessitating TSA. Shoulder 
pathology rates are increasing and so are costs associated with them. In 2006, the costs for 
musculoskeletal diseases was 4.5% of GDP or $576 billion. Patients complaining of chronic 
shoulder conditions represented 8.2% of the US population or 18.9 million adults (AAOS, 2011; 
CMS, 2011).  Current literature suggests there are approximately 39,000 TSAs performed 
annually (Day et al., 2015; Kim et al., 2011; Ponce et al., 2015). Cost estimates for a TSA vary 
widely, from $14,000 to $52,000 per patient, with the average 4-year total cost at $17,587 (Ponce 
et al., 2015; Verani et al., 2013; Davis et al., 2014). Thus, the total annual costs of TSAs in the 
United States range from $490 million to $1.8 trillion. (Ponce et al., 2015; Verani et al., 2013; 
Davis et al., 2014). 
Total Shoulder Arthroplasty & Cost Savings 
 Research has proven outpatient orthopedic procedures to be cost-effective. Crawford et 
al. (2015) performed a systematic review of the literature evaluating outpatient orthopedic 
procedures and found an average cost savings of 17.6 - 56.6%.  Furthermore, research has shown 
TSAs and hemiarthroplasties to be cost-effective also. Mather et al. (2011) conducted a cost-




 Although inpatient TSA has been shown to be cost-effective, it is still a costly procedure. 
Eliminating costs associated with inpatient procedures could decrease costs and increase value. 
Inpatient admission costs, after a TSA, could vary from $1500 - $12,500 per day (Steinhaus et al. 
2018). Steinhaus et al. (2018) created a model to estimate cost savings for performing TSAs in 
an outpatient setting, instead of in an inpatient setting, by looking at the literature, estimating a 
cost savings of between $747 and $15,507 per outpatient TSA is likely. They extrapolated this 
out to an annual cost savings ranging from $4 to $349 million, with a potential 10-year potential 
savings for outpatient TSA between $51 million to $5.4 billion (Ibid.).  
 To date, there has been only one study which directly evaluated the costs associated with 
outpatient TSA and comparing those costs to the costs of inpatient TSA. The one study which do 
so was conducted by Cancienne et al. (2017), who performed a retrospective analysis of  4,459 
propensity score matched patients receiving outpatient TSAs to compare the costs of those 
undergoing the procedure in an outpatient versus inpatient setting, using with ICD-9 codes. The 
authors excluded reverse total shoulder arthroplasty, acute proximal humerus fractures, and 
osteonecrosis of the proximal humerus. They found for those matched patients undergoing 
outpatient TSA there was a cost savings, as the median cost was $14,722 for outpatient and 
$18,336 for inpatient, controlling for the following: sex, 10-year age group, tobacco use, obesity, 
chronic kidney disease, coronary artery disease, chronic anemia, and diabetes. This amounts to a 
cost savings of $3,614 per case, which is a 19.7% cost reduction over having the surgery done in 
an inpatient setting.  
 There were no differences in outpatient TSA and inpatient TSA while comparing all 
postoperative complications (p.<.05). The control group had a lower rate of urinary tract 




control group had a higher rate of medical and systemic complications postoperatively at 90 days 
(15.9%,17.7%) (p<0.012). The risk factors for readmission following outpatient TSA in this 
study were peripheral vascular disease (OR, 1.7; 95% CI: 1.14-2.66, p=0.025), diabetes (OR, 1.5; 
95% CI: 1.17-1.98, p=0.025), chronic lung disease (OR, 1.8; 95% CI: 1.09-2.88, p=0.021), 
congestive heart failure (OR, 2.0; 95% CI: 1.16-3.52, p=0.014), depression (OR, 2.4; 95% CI: 
1.54-3.80, p<0.0001), and chronic anemia (OR, 2.2; 95% CI: 1.36-3.47, p=0.001). There were a 
multitude of risk factors for readmission for inpatient TSA. The risk factors were similar to the 
outpatient findings,  including greater than 80 years old.  
 The limitations of this study relate to the use of large database analyses. First, the 
accuracy the information and the quality of the reporting in the database. Second, certainly, there 
is some degree of selection bias in selecting younger and healthier patient for outpatient TSA. 
Third, there are some regional inconsistencies in reimbursement rates across the US, thus 
affecting some of the cost analyses. However, this study also had some strengths. First, used a 
large database for privately insured and Medicare patients. Second, the study included a large 
cohort of 4,459 propensity score matched patients. Third, the study covered from 2010 to 2014, 
providing a good time frame. Fourth, the authors appropriately matched both groups and used 
multivariate regression to analyze the data.  Overall, this was a well-designed study with reliable 
and valid results. 
 Currently, Cancienne et al.(2017) is the only published study comparing costs of  
outpatient versus inpatient TSA.  The study was performed shortly after the implementation of 
the Affordable Care Act and was utilizing ICD-9 data from 2010 through 2014, prior to the 
implementation of ICD-10. Using ICD-10 data will help identify more detailed data related to 




laterality is built into ICD-10 data. The present research need is to understand the differential 
costs between TSAs performed in an outpatient versus inpatient setting. Secondarily, an 
examination of the rates of complications between these two surgical settings to ensure 
equivalent quality across these two settings still exists, or if one setting is superior to another. 
Further, this research will assist future healthcare providers in determining whether outpatient 
TSA is indeed less costly than inpatient TSA. Yet, there should be more effort in evaluating the 
cost of outpatient TSA with ICD-10 in lieu of the Affordable Care Act and if its less costly than 
inpatient TSA. This will become increasingly important with BPCI and increased interest in 
value-driven care. Stakeholders in TSA, such as orthopedic surgeons, hospitals, and insurance 
companies each share an interest in the results of BPCI and potential value of outpatient TSA as 






Specific Aims and Hypotheses 
 This study’s research hypotheses were designed to explore costs after total 
shoulder arthroplasty and provide information germane to outpatient versus inpatient 
TSA. and those variables that account for differences in costs. Expressly, the research 
hypotheses were developed to discover which setting for TSA showed higher costs, 
inpatient, ambulatory, or outpatient TSA. Outpatient TSAs are those procedures that are 
done at the hospital and the patient is discharged to home the same day. Ambulatory 
TSAs are those procedures done in an ambulatory surgery center. Lastly, inpatient TSAs 
are those procedures done in a hospital and the patient remains 24 hours. Between these 
setting, we will examine the HIM distribution for each of these procedures. Furthermore, 
which comorbidities create the highest risk for costly complications and readmissions 
following TSA.  Therefore, there is increased risk for selection bias. Choosing patients to 
undergo outpatient TSA requires choosing those patients who are healthy and are likely 
to be privately insured.  The propensity-score matching will be used to match these 
patients and account for this bias.  
Aim 1 
To compare the safety of outpatient versus inpatient total shoulder arthroplasty among 




Hypothesis 1 (H1): Patients who undergo total shoulder arthroplasty in an 
outpatient setting will have lower complication rates than those in an inpatient 
setting.  
Hypothesis 2 (H2): Patients who undergo total shoulder arthroplasty in an 
outpatient setting will have lower readmission rates than those in an inpatient 
setting. 
Aim 2 
 To determine if outpatient total shoulder arthroplasty offers a cost advantage over the 
inpatient setting among patients with similar preoperative risk. 
Hypothesis 3 (H3):  Patients who undergo total shoulder arthroplasty in an 
outpatient setting will have lower costs than those in an inpatient setting. 
Study Design  
 A retrospective analysis of archival billing for patients undergoing total shoulder 
arthroplasty (TSA) will be conducted to analyze administrative data for cost and safety 
differences between TSAs performed an inpatient versus outpatient setting. The primary 
aim of the study is to compare cost for well-matched groups of patients receiving TSA in 
outpatient and inpatient settings. 
 Baseline characteristics will be comparably matched and variables influential to 
the costs associated with TSA such as sex, age, comorbidities, complications, and 
readmissions were also measured. Using a 1:1 propensity score matching ratio will 
provide the necessary balance for covariates in the study (Hanna et al., 2008).  Accurately 




this occurring, shows the power of a study (Shi, 2008). Relationships between the 
aforementioned variables will be analyzed. The secondary aim of this study will be to 
analyze those variables that significantly contribute to the cost of TSA.  
Population and Sample 
 All inpatient discharges from selected states with an index admission for a total 
shoulder arthroplasty (TSA) were used for analysis. Archival data were obtained from 
Medicare 5% limited data set and MarketScan privately insured billing data from 2016. 
 The data were deidentified. The Medical University of South Carolina (MUSC) 
Institutional Review Board has previously classified studies that use these data as non-
human research.  
  This study utilizes the Centers for Medicare and Medicaid services (CMS) 
definition for elective anatomic total shoulder arthroplasty, which is defined as having a 
CPT code of 23472 or ICD-10 PCS procedure Z96.611 (left/right TSA) or Z96.612—
which is part of Diagnostic Related Group (MS-DRG v35.0) in 2016. This cohort will 
include all patients who received an anatomic TSA during 2016 and will have a 6 month 
pre-index period and a 12 month post-index utilizing private insurance, Medicare, and 
Medicaid. Patients who underwent reverse TSA (RTSA) and hemiarthroplasty will be 
excluded from the study as these patient populations can be different than those seeking 
elective anatomic TSA secondary for osteoarthritis. 
 Patients will be excluded if they meet any of the following exclusion criteria: 
Patients with the diagnosis of acute proximal humerus fracture (S42.201A) or 











 Two databases will used for data analysis in this project. Patients aged 55-64 will 
be extracted from the Truven Health MarketScan® Commercial Claims And Encounters 
(CCAE) database. Patients aged 65-74 will be extracted from the MarketScan® Medicare 
supplemental insurance database. Below is a description of these databases from the 
Truven Health MarketScan® Analytics Commercial Claims and Encounters Medicare 
Supplemental User Guide Data Year 2015 Edition.  
The Truven Health MarketScan® Research Databases capture person-specific 
clinical utilization, expenditures, and enrollment across inpatient, outpatient, 
prescription drug, and carve-out services. The data come from a selection of 
large employers, health plans, and government and public organizations. The 
MarketScan® Research Databases link paid claims and encounter data to detailed 
patient information across sites and types of providers and over time. The annual 
medical databases include private-sector health data from approximately 350 
payers. Historically, more than 20 billion service records are available in the 
MarketScan® databases. These data represent the medical experience of insured 
employees and their dependents for active employees, early retirees, Consolidated 
Omnibus Budget Reconciliation Act (COBRA) continues, and Medicare-eligible 








 Commercial Claims and Encounters Database 
The MarketScan® Commercial Claims and Encounters Database contains data 
from active employees, early retirees, COBRA continuees, and dependents 
insured by employer-sponsored plans (i.e., persons not eligible for Medicare). 
 Medicare Supplemental  
The MarketScan® Medicare Supplemental and Coordination of Benefits (COB) 
Database is created for Medicare-eligible retirees with employer-sponsored 
Medicare Supplemental plans. This database contains predominantly fee-for-
service plan data. (MarketScan 2015, p. 3). 
The MarketScan® databases used are deidentified. The Medical University of 
South Carolina (MUSC) Institutional Review Board has previously classified studies that 
use these data as non-human research. 
Definition of Variables 
 The outcome variable for H3 in this study will be costs for TSA patients, defined 
as the 90-day period following TSA. These costs will include itemized reimbursements 
and grouped DRG reimbursements for TSA. Itemized reimbursements will include the 
following: surgery, anesthesia, PACU observation (admission/discharge), radiology 
(intraoperative/postoperative), laboratories (intraoperative/postoperative), physical 
therapy/occupational therapy (inpatient/outpatient), home healthcare, and prescription 
medications (Cancienne et al., 2017). The outcomes for H1 and H2 will be binary 




for those patients with > 2 comorbid conditions. The hospital readmission period starts on 
the day the patient is discharged from said facility. This period ends on day 91 following 
discharge (Cancienne et al., 2017; CMS, 2018). 
 Potential covariates for costs associated with inpatient and outpatient TSA are  
comorbidities such as, hyperlipidemia, hypertension, diabetes, congestive heart failure, 
peripheral vascular disease, coronary artery disease, chronic lung disease, chronic kidney 
disease, chronic liver disease, depression, inflammatory arthritis, hypercoaguable 
disorder, hypothyroidism, hemodialysis, and chronic anemia (Cancienne et al., 2017; 
Famg, Zingmond, Krenek, Soohoo, 2011; Waterman et al., 2015). Other independent 
variables such as sex, race, age, postoperative complications, and readmissions. 
 These complications have been reported in other matched database studies 
evaluating TSA. Post-operative medical complications after a TSA will include venous 
thromboembolism, pulmonary embolism, lower extremity deep venous thrombosis, 
urinary tract infection, pneumonia, myocardial infarction, acute renal failure, 
cerebrovascular accident, and blood transfusion. Shoulder-specific complications after 
TSA included infection with 90 days of procedure, dislocation within 90  days, loosening 
within 90 days, stiffness within 90 days, periprosthetic fracture within 90 days, and 
revision total shoulder arthroplasty within 90 days, and open and closed reduction within 
90 days. Hospital readmissions within 90 days postoperatively will be measured (AHRQ, 
2018; Cancienne et al., 2017; Famg, Zingmond, Krenek, Soohoo, 2011; Waterman et al., 




 The comorbid conditions matched and controlled for in this study may include 
diabetes, tobacco use, obesity, sex, age group (grouped in decades), coronary artery 
disease, chronic kidney disease, and chronic anemia diagnosis inside of a year of the 
TSA, Charlson Comorbidity Score, and Seamon Frailty Score (Cancienne et al., 2017; 
Famg, Zingmond, Krenek, Soohoo, 2011; Waterman et al., 2015). 
Table 1 ICD-9 Codes for comorbid conditions 
Description Code 
Demographics characteristics  
Obesity 278.00, V85.30-V85.39 
Morbid Obesity 278.01, V85.40-V85.45 
Tobacco Use 305.1 
Alcohol Abuse 303.x, 305.00-305.03 
Comorbidities  
Chronic Anemia 280, 281.2, 285.2, 285.8-285.9 
Chronic Kidney Disease 585.1-585.6, 585.9 
Chronic Liver Disease 571.0-571.6, 571.8-571.9 
Chronic Lung Disease 491.0-491.2, 491.9, 492.0, 492.8, 496 
Congestive Heart Failure 428 
Coronary Artery Disease 414.00-414.07, 414.2-414.4, 414.8-
414.9 
Depression 300.4, 301.12, 309.00, 309.1, 311 
Diabetes Mellitus 250 (250.00-250.39) 
Hemodialysis 585.5-585.6, V45.11-V45.12, 39.95 
Hypercoaguable Disorder 286.9, 289.81-289.82 
Hyperlipidemia 272.0-272.9 
Hypertension 401.x-405.x 
            Hypothyroidism 243, 244 
            Inflammatory Arthritis 696.0, 714.0, 720.0 
            Peripheral Vascular Disease 443.9 







Table 2 ICD-10 codes for comorbid conditions 
Description ICD-10 Codes 
Demographic Characteristics  
Obesity E66.9, Z68.30-Z68.39 
Morbid Obesity E66.01, Z68.40-Z68.45 
Tobacco Use F17.200 
Alcohol Abuse F10.10 
Comorbidities  
Chronic Anemia D51.1, D51.3, D51.8, D52.0, D52.1, D52.8, 
D52.9, D64.4, D64.89, D64.9 
Chronic Kidney Disease N18.1-N18.6, N18.9 
Chronic Liver Disease K70.0-K70.6, K76.0, K76.89, K74.1, K76.9 
Chronic Lung Disease J41.0-1, J41.8, J42, J43.9, J44.9 
Congestive Heart Failure I50.9 
Coronary Artery Disease I25.10, I25.810, I25.811, I25.812, I25.82, I25.83, 
I25.84, I25.5, I25.89, I25.9 
Depression F34.1, F43.21, F32.9 
Diabetes Mellitus E11.8, E11.9, E10.9, E11.65, E10.65, E11.69, 
E10.10, E11.00, E11.01, E10.69, E11.641, 
E10.11, E10.641, E10.11, E11.29, E10.29, 
E11.21, E11.311, E11.319, E11.36, E11.39, 
E10.311, E10.319, E10.36, E10.39, E11.40, 
E10.40, E11.51, E10.51, E11.618, E11.620, 
E11.621-622, E11.628 ,E11.630, E11.638, 
E11.649, E11.65, E11.69, E10.618, E10.620-622, 
E10.628, E10.630, E10.638, E10.649 
Hemodialysis N18.5, N18.6, Z99.2, Z91.15 
Hypercoaguable Disorder D68.8, D68.9, D68.51, D68.52, D68.59, D68.61, 
D68.62, D68.69 
Hyperlipidemia E78.0-E78.9 
Hypertension I97.3, I10, I15.0, I15.8, I15.9, I12 
Hypothyroidism E00.9, E03.9 










Table 3 ICD-10 and CPT codes for postoperative complications 
Description Codes 
Medical  
Acute Myocardial Infarction I21.09, I21.19, I21.11, I21.29, I21.4, 
I21.3 
Acute Renal Failure N00.3, N17.0-N17.4, N19 
Blood Transfusions CPT: 36430; ICD-10: T80.89XA 
Cerebrovascular Accident 60.9, I62.1, I62.00, I62.9, I65.1, I63.22, 
I65.29, I63.139, I63.239, I65.09, I63.019, 
I63.119, I63.219, I65.8, I63.59, I65.8, 
I63.20, I65.9, I66.09, I66.19, I66.29, 
I63.30, I66.9, I63.40, I63.50 
Deep Venous Thrombosis, Lower-
Extremity 
I82.409, I82.419, I82.429, I82.439, 
I82.4Y9, I82.449, I82.499, I82.4Z9 
Deep Venous Thrombosis, Upper-
Extremity 
I82.629, I82.609, I82.A19, I82.B19 
Pneumonia J12.0-J12.1, J13, J18.1, J15.0-J15.9 
Pulmonary Embolism I26.90, I26.99 
Urinary Tract Infection A54.00, A54.29, A54.21, N39.0, 
T83.51XA 
Shoulder-Specific CPT: 36430; ICD-10: T80.89XA 
            Periprosthetic Fracture T84.049A 
Periprosthetic Loosening T84.029A 
Postoperative or Periprosthetic 
Infection 
CPT: 10180, 20005, 23030, 23031, 
23040; ICD-10: M00.019, M00.119, 
M00.219, M00.819, M01.X19, M01.X19, 
T84.50XA, T84.60XA, T84.7XXA, 
T85.79XA, T81.4XXA, K68.11, 
T81.4XXA 
Revision Shoulder Arthroplasty CPT: 23473, 23474; ICD-10: Z96.611-
612 




M24.419, S43.006A, S43.016A, 
S43.026A, S43.036A 
Shoulder Stiffness CPT: 23700; ICD-10: M24.619, 
M25.619, M75.00 







 Two datasets will be used in this study. The first dataset is the 2016 Medicare 5% 
limited data set.  
 The second dataset is the Truven Health MarketScan® privately-insured database. 
 These datasets were abstracted for clinical, demographic, and cost data for TSAs 
performed in 2016. All of this data was covered by ICD-10 and current CPT codes. This 
data are available through the Agency for Healthcare Research and Quality (AHRQ) and 
the Healthcare Cost and Utilization Project (H-CUP) to The Medical University of South 
Carolina and is facilitated by Dr. Kit Simpson. The training required by H-CUP was 
completed by the student and signed the user data agreement. 
 The variables analyzed within these datasets were age, sex, race (available in 
HCUP, not in MarketScan®), medical comorbidities (see table I), complications, risk 
factors for readmission and 90-day costs following the procedure. 
Data Analysis 
 H3 will utilize using a gamma-distributed log-link model and linear regression 
models to evaluate costs. H1 and H2 will be using logistic regression models and odds 
ratios to compare binary variables and outcomes such as demographics (age, sex, payor), 
risk factors and reasons for readmissions, and complications for outpatient and inpatient 
TSA patients (Cancienne et al., 2017). Odds ratios (OR) will be calculated for the 
continuous variables of interest with 95% confidence intervals (CIs) and significance will 




modified Poisson regression model with robust error variance estimation (‘sandwich error 
variance’; Zhou, 2004) was used to yield risk ratios. 
 Total cost and all medical bills for 90 days post-surgery will be compared and will 
include the following: institutional fees, and surgical fees will be evaluated and compared 
for outpatient and inpatient TSA including: surgery (surgical CPT code), concomitant 
procedures, anesthesia, intraoperative and postoperative imaging, PACU observation, 
discharge, intraoperative and postoperative laboratories and pathology, inpatient and 
outpatient physical therapy and occupational therapy, home health (excluding physical 
and occupational therapy), follow-up visits, pharmaceuticals (narcotics, anti-
inflammatories, muscle relaxants, antibiotics, anticoagulants, antiemetics), and grouped 
reimbursements DRG (Cancienne et al., 2017). The cost of care associated with these 
morbidities should be the same. Student T-test will be used to compare mean cost data 
per patient comparing outpatient and inpatient TSA patients. Chi square testing will be 
used for categorical variables. All analyses will be performed using SAS 9.4 (Cary, NC) 
and SPSS v. 24 for Apple (Armonk, NY). 
Limitations 
 Administrative data are generated from medical claims produced by bills and 
reimbursement for those bills. Largely, this data is considered reliable, especially data 
that is derived from reimbursements or payments. However, there are also limitations 
associated with this type of data.  This study utilizes claims data from Medicare and 
commercial insurance payers. According to ResDAC, Research Data Assistance Center, 




1. Record of Care Received - The data is dependent upon only those diagnoses that 
are reported. As result, there may be certain pathologies that are underreported by 
the patient or the provider, thus increasing bias. 
2. Diagnosis Information – The information provided in the administrative record 
may not be comprehensive or detailed enough to provide accurate analysis of the 
data.  
3. Inconsistencies in the Use of Coding Systems by Care Setting – The difficulties 
associated with pairing CPT codes, ICD-9, and ICD-10 create challenges with the 
accuracy of using this data.  
4. Exclusions in Utilization Data – For example, until recently prescription drug data 
was not included, unsubmitted claims for rendered services, services not covered 
by Medicare, until recently services under Medicare part B were not included, 
until recently those in managed care were not included, aspects of Medicare part 
D are excluded, payments to providers is not provided by encounter data. 
5. Variable Quality – Generally, the information is considered good quality if it 
influences payments. 
Generally, when using administrative data it is recommended to use data dictionaries as a 
source of consistency, reliability, and quality. This will help to ensure your data is less 








 The leading indication for OA is total joint arthroplasty (TJA) (Sloan & 
Hanrahan, 2014; Kurtz, et. al., 2007). As the prevalence of OA continues to increase, so 
will the need for TJA surgery. Shoulder osteoarthritis, in particular, and the resulting 
treatment of total shoulder arthroplasty (TSA), has grown at a rate of 9.4% annually in 
the United States and is projected to exceed that of total knee arthroplasty (TKA) and 
total hip arthroplasty (THA) (Day et al., 2010). 
 Historically, TJA and TSA have proven to be safe procedures. Surgeons have 
translated their good outcomes from inpatient TJA into the outpatient setting with good 
results. These outcomes have motivated orthopedic surgeons to increase the use of TSA 
in the outpatient setting as well (Berger et al., 2009; Courtney et al., 2016). In the 
outpatient setting, it is vital to avoid costly complications and readmissions. 
Postoperative complications and unplanned hospital admissions following outpatient TJA 
and TSA can increase costs following the procedure. In turn, this will decrease the value 
associated with outpatient TSA 
 Decreasing costly complications will decrease the costs associated with inpatient 
TSA such as overnight charges, hospital charges, nursing, labs, and medications 
(Crawford, Li, Sprague, & Bhandari, 2015) In fact, Previous studies have shown the three 




in the hospital (Bosco, et al., 2014; Healy et al., 1998; Healy et al., 1998; Raphael et al., 
2014; Steinhaus et al., 2018). While intraoperative costs, such as operating room time and 
surgical implants may be common to both inpatient and outpatient TSA surgery, 
elimination of the inpatient stay altogether can eliminate the third major cost driver— 
assuming the correct patients are chosen for outpatient TSA.  
 Using protocols and care pathways to educate patients, identify high-risk patients 
for complications, and redirecting those patients toward inpatient TSA is paramount to 
successful implementation of outpatient TSA (Kim and Iorio, 2017; Brolin and 
Throckmorton, 2018; Lombardi et al., 2016). Protocols and pathways will encourage 
value by decreasing costs and improving outcomes by encouraging only high-risk 
patients to have their surgeries performed in the inpatient setting; low risk patients would 
be encouraged to have their surgery performed in an outpatient setting, decreasing costs.   
 Healthcare spending in the United States is increasing dramatically and healthcare 
leaders are looking for ways to decrease costs and encourage value. Current spending in 
the US is nearly $3.5 trillion annually, or nearly 18% of the Gross Domestic Product 
(Berland, Rocco & Walden, 2015; Bryan, 2016). Therefore, value is crucial to the future 
to of our healthcare system. Value is defined as “health outcome per dollar of cost 
expended” (Porter & Olmsted-Teidsberg, 2006, p.4). Therefore, healthcare experts are 
focused on finding strategies to improve outcomes and decrease costs. According to 
Porter & Olmstead-Teidsberg, they believe “the structure of healthcare delivery” is 





 TJA is the largest procedural consumer of Medicare’s budget at 6.3% annually 
(Dobson et al., 2012). Outpatient TSA is one way to decrease these costs and increase 
value for consumers to ensure the solvency of the US healthcare system. To date, there 
has been little work focused on comparing outpatient TSA versus inpatient TSA and the 
potential cost savings. This study will ameliorate this problem by selecting only patients 
in both inpatient and outpatient settings who could genuinely have their surgery done in 
the outpatient setting; as all of the patients in this study are not high risk. 
 TJA is the largest procedural consumer of Medicare’s budget at 6.3% annually 
(Dobson et al., 2012). Outpatient TSA is one way to decrease these costs and increase 
value for consumers to ensure the solvency of the US healthcare system. To date, there 
has been little work focused on comparing outpatient TSA versus inpatient TSA and the 
potential cost savings. This study will ameliorate this problem by selecting only patients 
in both inpatient and outpatient settings who could genuinely have their surgery done in 
the outpatient setting; as all of the patients in this study are not high risk. 
 As value is becoming increasingly important, healthcare leaders must continue to 
seek out and find ways to balance cost savings with uncompromising patient safety. 
Outpatient TSA should not be an option for every patient; likewise, inpatient TSA should 
not be a consideration for every patient. Healthcare providers and patients need to be 
responsible enough to avoid costly errors by treating those patients with significant 
medical risks as inpatient. However, providers and patients should also encourage value 
by facilitating outpatient TSA for those patients who qualify. As our population ages, 




TSA, which will drive up healthcare costs. Therefore, healthcare leaders should strive to 
ensure this procedure is delivered in the most cost-effective manner. 
  
 The primary goal of this study was to determine the marginal cost differences and 
complication rates of total shoulder arthroplasty performed in an outpatient setting 
compared with that same procedure performed in an inpatient setting in a well-matched 
group of low to medium preoperative risk patients; these are patients whose surgery 
could have been performed in either an inpatient or outpatient setting. The authors 
hypothesized that the rate of complications would be lower in the outpatient setting. The 
authors also hypothesized costs would be lower in the outpatient setting. 
Methods 
 Data 
   This retrospective study was conducted using the two databases: Truven Health 
MarketScan® Commercial Claims and Encounters database (patients aged 55-64), as well 
as the Truven Health MarketScan Medicare supplemental insurance database (patients 
aged 65-74) for the 2016 claims year were used. These data included health insurance 
claims across the continuum of care (e.g., inpatient, outpatient, outpatient pharmacy, 
carve-out behavioral health care) as well as enrollment data from >100 large employers 
and health plans across the United States who provide private health care coverage for 
more than 50 million employees, their spouses, and dependents. This administrative 
claims database also includes a variety of fee-for-service, preferred provider 




The enrollment data provided beneficiaries’ demographic data including age, 
employment status, geographical region, and sex. These data also provided the 
beneficiaries’ insurance plan data including plan type and enrollment status. Medical 
service claims provide detailed inpatient and outpatient encounter information, including 
date and setting of service, provider type, plan and patient-paid amounts, International 
Classification of Diseases, 10th revision, Clinical Modification & Procedure Coding 
System (ICD-10-CM/PCS) diagnosis and procedure codes, Current Procedural 
Terminology, 4th edition (CPT-4) codes, and Healthcare Common Procedure Coding 
System (HCPCS) procedure codes. 
The MarketScan® databases used were deidentified. The Medical University of 
South Carolina (MUSC) Institutional Review Board has previously classified studies that 
use these data as non-human research. The Medical University of South Carolina 
(MUSC) Institutional Review Board has previously classified studies that use these data 
as non-human research.  
Study & Control Cohorts 
 Patients meeting the Centers for Medicare and Medicaid services (CMS) 
definition for elective anatomic total shoulder arthroplasty during 2016 were included in 
this study. This definition includes having a CPT code of 23472 or ICD-10-PCS 
procedure Z96.611 or Z96.612 (left or right, respectively). Patients had to be continually 
insured for 6 months pre-TSA and 3 months post-TSA. The patient’s first claim date for 
TSA served as the index date, and the patient was followed for 3 months post-TSA to 




reverse TSA and hemiarthroplasty were excluded from the study, as these patient 
populations can be different than those seeking elective anatomic TSA secondary to 
osteoarthritis. Patients were further excluded if they had an acute proximal humerus 
fracture (S42.201A) or osteonecrosis of the proximal humerus (M87.811). 
Propensity score matching 
 Propensity score matching was used as the study design method to model the 
probability that a patient could have had his or her surgery in the outpatient setting, to 
ensure only those patients who could have reasonably had their surgery in the inpatient or 
outpatient setting entered the study. We used a Greedy (nearest neighbor) 1:1 matching 
algorithm without replacement with the caliper distance of less than 0.1 standard 
deviations of the logit. The comorbid conditions matched and controlled for in this study 
included diabetes, tobacco use, alcohol use disorder, obesity, sex, age group (grouped in 
decades), coronary artery disease, chronic kidney disease, and chronic anemia diagnosis 
inside of a year of the TSA, Charlson Comorbidity Score, and Seamon Frailty Score (See 
Tables 1-3) (Cancienne et al., 2017; Famg, Zingmond, Krenek, Soohoo, 2011; {Seamon, 
Publication forthcoming}; Waterman et al., 2015).   
Outcomes 
 Our primary outcome was any post-operative medical or surgical complication in 
the 90 days following the procedure. Medical complications included venous 
thromboembolism, pulmonary embolism, lower extremity deep venous thrombosis, 
urinary tract infection, pneumonia, myocardial infarction, acute renal failure, 




included infection, dislocation, loosening of implant, stiffness, periprosthetic fracture, 
and revision TSA, and open or closed reduction.. Diagnosis codes for the complications 
are listed in Table I. 
 Our secondary outcome was total amount paid in the 90 days following the 
procedure. These included all inpatient and outpatient insurance payments, including for 
prescription medications and rehabilitation. Since the groups being compared were 
propensity score matched, the marginal cost of care between inpatient and outpatient 
cohorts should reflect the difference associated with the surgical setting and care 
following the procedure, and not of underlying comorbid burden. 
Statistical Analysis 
  Descriptive statistics were used to compare the characteristics of the two cohorts 
both pre- and post-matching. Means and standard deviations were calculated to describe 
continuous data; frequencies and percentages were calculated to describe categorical 
data. Chi-square statistics were used to test for differences in proportions. Two-sample 
Student’s t-tests were used for normally-distributed data and Wilcoxon rank-sum/Mann-
Whitney U statistics were used to test for differences in medians (or ranks) of non-
normally distributed continuous data.  
 Patient-specific variables considered for inclusion in regression models included 
age (grouped as 55-64 and 65-74), sex, geographic region, and Charlson comorbidity 
score. Race and ethnicity are not available in MarketScan databases. Consistent with 
prior studies, we also examined comorbidities such as, hyperlipidemia, hypertension, 




chronic lung disease, chronic kidney disease, chronic liver disease, depression, 
inflammatory arthritis, hypercoaguable disorder, hypothyroidism, hemodialysis, and 
chronic anemia (See Tables 1-3) (Cancienne et al., 2017; Famg, Zingmond, Krenek, 
Soohoo, 2011; Waterman et al., 2015). 
For the primary outcome, multiple logistic regression was used to compare the 
complication rates between the inpatient and outpatient settings. The main independent 
variable in these regressions was a binary indicator of whether the surgery occurred in the 
inpatient setting. Covariate adjustment was used to control for differences in rates of 
failure which may be attributable to other factors. Covariates were assessed for 
collinearity using Pearson correlation coefficients; no collinearity was found in these data 
(all p > 0.25). This model was then re-run using a modified Poisson regression model to 
provide more robust adjusted Odds Ratios (OR) and corresponding 95% confidence 
interval estimates. As overall risk of any complication was a rare event, a modified 
Poisson regression model with robust error variance estimation (‘sandwich error 
variance’; Zhou, 2004) was used to yield risk ratios. 
For the secondary outcome, a gamma-distributed log-transformed generalized 
linear model was ran. Covariates were selected for inclusion and examination for 
confounding on the basis of clinical relevance. Traditional model fitting procedures 
(Akaike Information Criterion and log-rank tests) were used to assess the value of each 
independent variable in the model. The final parsimonious models included independent 




All analyses were performed using SAS version 9.4 (Cary, NC) and SPSS v. 24 
for Apple (Armonk, NY). Statistical significance was set a priori at α<0.05. The 
institutional review board of the Medical University of South Carolina reviewed this 
study protocol and approved it as nonhuman subjects research, given the deidentified 














Male 224 (59.9) 659 (54.7) .079 
Age Group   .055 
   55-64 266 (71.1) 792 (65.8)  
   65-74 108 (28.9) 412 (34.2)  
Diabetes, complicated 22 (5.9) 69 (5.7) .913 
Diabetes, uncomplicated 43 (11.5) 164 (13.6) .288 
Hypertension, complicated 7 (1.9) 28 (2.3) .603 
Hypertension, uncomplicated 184 (49.2) 585 (48.6) .837 
Obesity 45 (12) 94 (7.8) .012 
Charlson Score 0.14 ±0.47 0.30 ±0.62 .000 
Frailty Category 
   Robust 
























Male 222 (60.2) 205 (55.6) .205 
Age Group   .339 
   55-64 261 (70.7) 249 (67.5)  
   65-74 108 (29.3) 120 (32.5)  
Diabetes, complicated 21 (5.7) 19 (5.1) .745 
Diabetes, uncomplicated 42 (11.4) 38 (10.3) .636 
Hypertension, complicated 7 (1.9) 6 (1.6) .780 
Hypertension, uncomplicated 182 (49.3) 179 (48.5) .825 
Obesity 51 (13.8) 48 (13.0) .746 
Urinary Tract Infection 12 (3.3) 4 (1.1) .043 
Readmission 5 (1.4) 0 (0.0) .025 
Any complication 35 (9.5) 16 (4.3) .006 
Charlson Score 0.14 ±0.47 0.11 ±0.38 .388 
Total Payments $13,514  
[$5,238 to $29,114] 
$32,992  
[$22,427 to $44,031] 
.000 







Table 6 Parameter Estimates for Total Costs in the 90-day period following surgery 
Parameter β 95% C.I. p-value 
Intercept  9.7503 (9.6282 – 9.8723) <.0001 
Inpatient 0.6268 (0.5155 – 0.7380 <.0001 
ETOH abuse -1.0329 (-2.5291 – 0.4634) 0.1761 
Tobacco use disorder 0.2361 (-0.1429 – 0.6151) 0.2220 
Obese 0.0833 (-0.0566 – 0.2231) .2432 
Frailty Category -0.0453 (-0.1599 – 0.0694) 0.4388 
Male 0.1132 (0.0008 – 0.2255) 0.0484 
Charlson score 1 0.4767 (0.2626 – 0.6908) <.0001 
Charlson score 2+ 0.4955 (0.1460 – 0.8450) 0.0055 
 
 
Table 7 Parameter estimates and odds ratio estimates for any complication 
 Parameter estimates  Odds ratios 
Parameter β 95% C.I. p-value OR 95% C.I. 
Intercept -2.337 -2.79 to -1.89 <.0001   
Inpatient -0.771 -1.34 to -0.20 0.008 0.436 0.261 to 0.818 
Diabetes 0.311 -0.39 to 1.01 0.382 1.346 0.680 to 2.742 
Obese -0.238 -0.963 to 0.488 0.521 0.789 0.382 to 1.630 
Male -0.164 -0.685 to 0.358 0.538 0.836 0.504 to 1.430 
Charlson score 1 0.176 -0.788 to 1.140 0.721 1.166 0.455 to 3.125 







We identified 1,578 patients who underwent TSA patients: 374 in the outpatient 
setting and 1,204 in the inpatient setting. After propensity score matching, 369 
participants in each group were used to compare the effect of surgery setting on 
complication rate and costs.  
Table 1 presents the differences between patients undergoing TSA in the inpatient 
versus the outpatient setting. Among these patients, the mean Charlson score was nearly 
double in the inpatient population (0.14 vs. 0.30, p<0.001). However, the outpatient 
population had higher rates of obesity than the inpatient group (12% vs 7.8%, p=.012). 
Propensity score matching yielded an overall 96.68% reduction in bias, with all 
covariates satisfying the minimum reduction in bias to an absolute standardized 
difference in means of less than 0.1 after matching. These propensity score matched 
patients then entered the study for analysis. 
Table 2 presents the differences between patients undergoing TSA and inpatient 
versus outpatient setting, among those propensity score matched and in the study. Among 
these, urinary tract infections were more frequent in the outpatient TSA group (3.3% vs 
1.1%, p=.043). Furthermore, there were more complications of any type for outpatient 
(9.5% vs 4.3%, p=.006) compared to inpatient and 3 times as many medical 
complications (5.7% vs. 1.6%, p=.003). Lastly, payments were substantially less for 
those patients undergoing outpatient TSA (Mean, $13,514 vs $32,992, p<0.001). 
 In the analysis to compare total amounts paid in the 90 days following surgery 
between inpatient and outpatient total shoulder arthroscopies, it was found that inpatient 




confounding factors of alcohol abuse, tobacco use disorder, obesity, frailty category, sex, 
and Charlson category (categorized as 0, 1, 2+). Total costs for inpatients were 87% 
higher at $36,033 vs. $19,253 for outpatient TSA (p=0.0001). Other significant 
contributors to cost differences included patients who were male (p=0.0484), and those 
with increased medical morbidities, as denoted by Charlson scores of 1 or 2+ (p<0.0001 
and p=0.0055, respectively). The analysis of maximum likelihood parameter estimates 
are found in table 3. 
 In the analysis to compare complication rates following surgery between inpatient 
and outpatient total shoulder arthroscopies, it was found that patients who had their TSA 
performed in an inpatient setting were at a 53.8% lower risk of a complication than those 
who had their TSA performed in an outpatient setting (Odds Ratio [OR] = 0.462, 95% 
CI: 0.261 to 0.818; p=0.008). In our modeling we also found that those with the Charlson 
score of 2 or greater had 3 times the odds of a complication over those whose Charlson 
score was zero (OR: 3.03, 95% CI: 1.18 to 7.75; p=0.021).  
Discussion 
 Current spending in the US is nearly $3.5 trillion annually, or nearly 18% of the 
Gross Domestic Product (Berland, Rocco & Walden, 2015; Bryan, 2016). Therefore, 
value is crucial to the future to of our healthcare system. However, this desire to increase 
value must be balanced with safety.  
 Outpatient TSA is one way to decrease these costs and increase value for 
consumers to ensure the solvency of the US healthcare system. Using protocols and care 




redirecting those patients toward inpatient TSA is paramount to successful 
implementation of outpatient TSA (Kim and Iorio, 2017; Brolin and Throckmorton, 
2018; Lombardi et al., 2016). These protocols and pathways will encourage value by 
decreasing costs and improving outcomes by encouraging only high-risk patients to have 
their surgeries performed in the inpatient setting; low risk patients would be encouraged 
to have their surgery performed in an outpatient setting, decreasing costs.  Moreover, it 
will create a perioperative environment promoting success by following the 
aforementioned principles for outpatient TSA patients, thus decreasing complications and 
unplanned hospital admissions. These complications and unplanned hospital admissions 
following inpatient and outpatient TSA can be costly. 
 It is extremely important to establish value for ambulatory, outpatient, and 
inpatient TSA; however, we must also corroborate the safety of outpatient TSA. 
Decreasing costly readmissions and visits to the ED is vital to the efficacy of outpatient 
surgery and to our healthcare system. So that outpatient TSA can be successful, we must 
establish protocols and pathways highlighting those patients best suited for the outpatient 
setting. These patients will have less comorbidities and will be less likely to be 
readmitted or visit the ED following discharge. 
 This study investigated whether outpatient TSA offers a cost advantage over 
inpatient TSA. Moreover, we examined which option had a higher risk of  readmissions 
and complications.  
 Hypothesis 1 (H1), is do patients who undergo total shoulder arthroplasty in an 




No, our study shows an increased rate of complications. There were more complications 
of any type for outpatient (9.5% vs 4.3%, p=.006) compared to inpatient and 3 times as 
many medical complications (5.7% vs. 1.6%, p=.003). UTI’s were more frequent in the 
outpatient TSA (3.3% vs 1.1%, p=.043). This could represent a lack of screening or less 
healthy patients being directed toward the outpatient setting. Likewise, there were more 
complications of any type for outpatient (9.5% vs 4.3%, p=.006) compared to inpatient 
and 3 times as many medical complications (5.7% vs. 1.6%, p=.003). These findings are 
contrary to Cancienne et al., which showed no differences in outpatient TSA and 
inpatient TSA while comparing all postoperative complications (p.<.05). The control 
group had a lower rate of urinary tract infection (6.8 <8.7%) (p<0.003) and blood 
transfusions (3.5%<4.7%) (p<0.028). Overall the control group had a higher rate of 
medical and systemic complications postoperatively at 90 days (15.9%,17.7%) (p<0.012). 
Each of these findings represent increased urgency to maintain protocols and pathways. 
Moreover, as healthcare leaders and clinicians we must be careful not substitute value for 
quality of care.  
 Recognizing those patients with risk factors and increased medical morbidity is 
paramount to maintaining the value associated with outpatient TSA. If patients have 
outpatient surgery and return to the hospital for readmission or ED, then costs will be 
higher (Chalmers et al., 2014; Courtney et al., 2017; Dunn et al., 2015, Waterman et al., 
2015). Other authors have shown a correlation between preoperative medical morbidities 




 Hypothesis 2 (H2), is do patients who undergo total shoulder arthroplasty in an 
outpatient setting will have lower readmission rates than those in an inpatient setting? 
No, patients in the outpatient setting have a higher readmission rate than those in the 
inpatient. Those patients requiring readmission were greater in the outpatient TSA group 
5(1.4) vs. 0(0.0); (p=.025). One way to ameliorate these risks factors, visits to the ED, 
and readmissions is by using protocols and pathways. Identifying high-risk patients by 
using standardized protocols requires a multidisciplinary approach. Using the CCI is one 
way to monitor medical risk factors and redirect high-risk patients toward the inpatient 
setting (Brolin and Throckmorton 2018; Chalmers et al., 2015; Kim and Iorio 2017; 
Lombardi et al. 2016). Our study showed patients with increased medical morbidity and 
Charlson Category Score +1 were nearly 48% (95% CI: 0.2626 – 0.6908; p<0.0001) 
more expensive and those patients with Charlson Category Score of +2 were 50% more 
expensive (95% CI: 0.1460 – 0.8450; p=0.0055). 
 Hypothesis 3 (H3),  is do patients who undergo total shoulder arthroplasty in an 
outpatient setting will have lower costs than those in an inpatient setting. Yes, payments 
were substantially less for those patients undergoing outpatient TSA (Mean, 19902.44 vs 
35931.47, p=.000). Exponentiated Costs are equal to the Total Paid, while adjusting for 
other covariates. Total exponentiated costs for inpatient were 87% higher at $36,033 
(95% CI: 33323 – 38963; p<0.0001), while outpatient TSA was $19,253 (95% CI: 17805 
– 20819; p=0.0001). These findings are consistent with other studies showing a cost 
savings with outpatient TSA (Aynardi et al. 2014; Cancienne et al. 2017; Crawford, Li, 




Cancienne et al. showed a  median cost savings of just $3614, while our findings were 
showed a much higher cost savings of $16,780. This difference could be attributed to 
ICD-10 and the ACA as our study included patients from 2016, while Cancienne et al. 
evaluated patients from 2010-2014 prior to ICD-10. 
 This study had several limitations. Many of them are broad and related to using 
administrative data. First, the record of care could be unreliable due to lack of 
documentation, thus skewing the information. Specifically, patients in this cohort could 
be seen within the 90 day postoperative period for minor complications with 
documentation, but without coding. (Cancienne et al., 2017; Resdac, 2018). Second, 
although ICD-10 is more detailed and this could also be considered a strength of this 
study, diagnostic information may not be comprehensive. Third, there could 
inconsistencies in coding or procedures with different clinical settings. Fourth, there are 
variables that cannot be controlled for such as surgical technique, hospital volume, 
operative time, and anesthesia. Further, while patients were matched, we could not 
control for those patients who were discharged and pursued their own care at outpatient 
or inpatient rehabilitation facilities. Fifth, patients were propensity score matched and 
multivariate regression was employed, but there was likely some selection bias in 
choosing healthier patients for outpatient TSA. Sixth, reimbursements could vary for 
TSA secondary to contracts, facilities, and geographic locations. Seventh, our 
complications encompassed 90 days postoperatively. Some of these complications may 
be more likely to occur after 90 days such as dislocation, periprosthetic fracture, 




rate. Eighth, we examined only one year of data, 2016. Finally, our study identified 
complications, but did not elaborate on specific complications (Cancienne et al., 2017; 
ResDac, 2018). 
 In conclusion, our results show that outpatient TSA provides a significant cost 
reduction. However, there was an increase in complications. This is contrary to previous 
work published by Cancienne et al. Therefore, future work should focus on evaluating 
outpatient TSA, its value, and its safety within ICD-10 and the ACA. Additionally, 
healthcare leaders should focus on identifying and directing high-risk patients toward 
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